Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

NCT05027776 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1348

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV Infections
Cervical Cancer Stage IIa
Vaginal Cancer
Genital Wart
CIN1
CIN2
CIN3

Interventions

BIOLOGICAL: 2-doses Group among 9-14 years
BIOLOGICAL: 3-doses Group among 9-19 years
BIOLOGICAL: 3-doses Group among 20-26 years

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.

Collaborators

[object Object]